A male in his early 20s with CCCA (scarring alopecia) started treatment with Finasteride, Fluocinolone, and Doxycycline. Steroid injections were suggested but not yet done.
The conversation discusses using topical cetirizine as a treatment for androgenetic alopecia (hair loss). Specific treatments mentioned include Minoxidil, finasteride, and RU58841.
PP405 is considered a potential new treatment for hair loss, compared to finasteride and minoxidil. There is skepticism about its effectiveness in humans, with anticipation for more information from an upcoming conference.
Severe scalp itching and hair loss, possibly linked to seborrheic dermatitis, are discussed, with treatments like Dutasteride, Finasteride, and various shampoos mentioned. Some users find relief from itching with DHT blockers like Finasteride, while others suggest consulting multiple dermatologists for accurate diagnosis.
Clascoterone is seen as a promising topical treatment for hair loss, similar to finasteride but without side effects, though concerns exist about its long-term effectiveness. Other treatments discussed include topical minoxidil, ketoconazole, microneedling, and oral options like dutasteride and minoxidil.
The user is exploring hair loss treatments in China, currently using finasteride and minoxidil, and is concerned about seborrheic dermatitis. Clinics are recommending selenium sulfide, doxycycline, and mesotherapy ampoules like PT88/PT66 or SP88/SP66, but the user is unsure about their effectiveness.
Finasteride and dutasteride can affect sexual function, cognition, and mood. Alternatives like minoxidil, pyrilutamide, and alfatradiol have varied effectiveness and side effects.
The user reports that using topical Dutasteride has stopped their hair loss, and they are curious about potential side effects and regrowth. They also mention having scalp psoriasis and past SSRI use affecting libido.
Hair loss is linked to a higher rate of body dysmorphic disorder (BDD), OCD, and depression. Finasteride and dutasteride are not linked to increased suicidal risk, though some users report mental health side effects.
The relative strength of Pyrilutamide compared to RU58841 in terms of androgen receptor binding affinity. It has been noted that Pyrilutamide is 4x stronger than RU58841, with a higher binding affinity than DHT itself.
The user experienced severe side effects from finasteride, including hormonal imbalances and cognitive issues, leading to a recommendation to stop its use. They plan to follow up with tests to rule out a pituitary tumor and are considering topical treatments as alternatives.
Researching the release of phase 2 trials for pyrilutamide, a potential hair loss treatment, and discussing other treatments such as Minoxidil, Finasteride, and RU58841.
PTD-DBM is a Korean-developed treatment for hair loss, with limited information available and some users testing it personally. A user purchased PTD-DBM for $115 and plans to test it on their temples, but its effectiveness and authenticity remain uncertain.
PP405 shows promise for hair regrowth by manipulating stem cell characteristics and lactate dehydrogenase, with Phase 2a trials pending. Google Ventures' $15M investment suggests confidence, but results and market availability remain uncertain.
The user discusses using essential oils like peppermint, rosemary, tea tree, and lavender to improve hair thickness and seborrheic dermatitis. They plan to add RU58841 to their routine and seek advice on using it alongside the essential oils without interference.
The conversation is about the double standard in the hair loss community regarding shedding when using different treatments. The conclusion is that shedding is considered normal when starting finasteride or minoxidil, but not when starting dutasteride, despite the fact that dutasteride is more effective at reducing DHT.
The user switched from finasteride to dutasteride and is seeking feedback on hair changes after 4 months. The current regimen includes oral dutasteride, oral minoxidil, and topical minoxidil.
RU58841 can be ordered as a powder and compounded at home, but it should be stored at room temperature to avoid crystallization. Pyraulatmide may follow a similar principle.
A female user's experience using Spironolactone to treat Female Pattern Hair Loss (FPHL) and Androgenic Alopecia, as well as discussing the effectiveness of the drug at different dosages.
The conversation discusses the difference between the commercially available Pyrilutamide and the version in clinical trials. It also mentions treatments like Minoxidil, finasteride, and RU58841 for hair loss.
RU58841, an anti-androgenic compound, showed early promise for treating alopecia but faced challenges after its patent in 1997. Despite advancing to Phase II trials, safety concerns and financial struggles led Aventis to abandon its development. Proskelia, which later merged into ProStrakan, couldn't prioritize the drug, leading to its eventual stagnation and failure to reach the market.
The user is considering using topical dutasteride to prevent hair loss progression from Norwood 1 to Norwood 2 at age 25, and is concerned about the long-term effectiveness and potential shedding from the treatment. They are currently using a shampoo with caffeine, rosemary, and saw palmetto, and have noticed hair thinning and changes since age 20.
User noticed beard and sideburn hair loss, and thinning eyebrows, diagnosed with alopecia barbae and male pattern baldness, and prescribed Desonide cream. User seeks feedback on Desonide cream.
A user was prescribed Alpicort E, which contains Estradiol Benzoate, Prednisone, and Salicylic Acid, for hair loss and is seeking others' experiences due to concerns about potential side effects.
The conversation discusses the less impressive results of Pyrilutamide (kx-836) in phase 3 compared to phase 2, with a suggestion that a longer study might show more significant results. One user reports personal success with Pyrilutamide, experiencing no further hair loss and gradual regrowth.
Spironolactone and finasteride are not recommended for women planning pregnancy due to birth defect risks. Both need to be stopped months before conception, and finasteride is generally not advised for women.